Results 81 to 90 of about 32,676 (224)

Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect

Frontiers in Pharmacology, 2016
We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, three months after switching anticoagulant from the vitamin K antagonist ...
Kuntheavy Ing Lorenzini, Youssef Daali, Pierre Fontana, Jules Desmeules, Caroline Flora Samer   +4 more
doaj   +1 more source

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk

, 2014
Sylvia Haas,1 Christoph Bode,2 Bo Norrving,3 Alexander GG Turpie4 1Technical University Munich, Munich, Germany; 2Department of Cardiology and Angiology, University of Freiburg, Freiburg, Germany; 3Department of Clinical Neuroscience, Lund University ...
Norrving B, Turpie AGG, Bode C, Haas S
core  

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations

, 2014
Ingo Ahrens, Christoph Bode Heart Center, University of Freiburg, Department of Cardiology and Angiology I, Freiburg, Germany Abstract: The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa ...
Ahrens I, Bode C
core  

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation

, 2011
BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment.
BECKER R. C, PAN G, HALPERIN J. L, HACKE W, CAROLEI, ANTONIO, SINGER E, MAHAFFEY K. W, PATEL M. R, J. P, PAOLINI J. F, AND THE ROCKET AF INVESTIGATORS, S. D, CALIFF R. M, GARG J, NESSEL C. C, FOX K. A, HANKEY G. J, BREITHARDT G   +17 more
core   +2 more sources

The impact of body weight on rivaroxaban pharmacokinetics [PDF]

, 2017
EssentialsThe optimal dosing strategy of rivaroxaban for patients at the extremes of body weight is not known.A pharmacokinetic study was conducted based in real-world patients in a London teaching hospital.In the cohort of patients studied, weight on ...
Jignesh P. Patel, Roberts, Lara, Roopen Arya, Green, Bruce, Sarah J. Barsam, Patel, Rajesh, Venu Kavarthapu, Lara N. Roberts, Kavarthapu, Venu, Bruce Green, Barsam, Sarah Joy, Patel, Jignesh Prakash; id_orcid, Arya, Roopen, Raj K. Patel   +13 more
core   +1 more source

Early Mobilization After Pacemaker Implantation

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd, Vlastimil Vančura, Martin Brada, Richard Rokyta   +3 more
wiley   +1 more source

Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome

, 2014
Marvin Krohn-Grimberghe, Christoph Bode, Constantin von zur MuhlenDepartment of Cardiology and Angiology I, Heart Center, University of Freiburg, GermanyAbstract: Angioplasty and stent implantation have greatly improved the outcome of patients with acute
Krohn-Grimberghe M, von zur Muhlen C, Bode C   +2 more
core  

A Case of Rivaroxaban Associated Intracranial Hemorrhage [PDF]

, 2014
Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin.
Lo, Jean CY, Roy R. Gerona, Gerona, Roy R, Jean Chin-Yu Lo   +3 more
core   +1 more source